Investigational Drugs

• Zoledronic acid (Zometa): This drug is an injectable bisphosphonate that can be administered annually for individuals unable to take or tolerate oral bisphosphonates. It is currently approved by the US Food and Drug Administration (FDA) for bone metastases in individuals with cancer.
  
  
• Etidronate (Didronel): This is another bisphosphonate approved by the FDA for treatment in Paget disease.
  
  
• Lasofoxifene: This is a SERM that decreases bone loss. It has favorable effects on blood cholesterol level and may prevent the growth of certain breast cancer cells.
  
  
• Basedoxifene: This is another SERM currently undergoing clinical trials.
  
  
• Strontium (Protos): This is an oral drug in development in Europe, Australia, and Japan. It decreases breakdown of bone and increases bone formation.